Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
0.5403
Dollar change
+0.0006
Percentage change
0.11
%
Index- P/E0.42 EPS (ttm)1.28 Insider Own12.91% Shs Outstand8.65M Perf Week-14.91%
Market Cap4.67M Forward P/E- EPS next Y- Insider Trans-75.28% Shs Float7.53M Perf Month-14.05%
Income3.06M PEG- EPS next Q- Inst Own3.53% Short Float2.40% Perf Quarter-3.54%
Sales23.79M P/S0.20 EPS this Y- Inst Trans-0.95% Short Ratio0.82 Perf Half Y-18.14%
Book/sh1.12 P/B0.48 EPS next Y- ROA11.25% Short Interest0.18M Perf Year-45.43%
Cash/sh0.27 P/C2.01 EPS next 5Y- ROE56.40% 52W Range0.36 - 1.50 Perf YTD-6.89%
Dividend Est.- P/FCF- EPS past 5Y55.67% ROI19.01% 52W High-63.98% Beta1.22
Dividend TTM- Quick Ratio2.56 Sales past 5Y- Gross Margin92.58% 52W Low48.15% ATR (14)0.05
Dividend Ex-Date- Current Ratio2.56 EPS Y/Y TTM107.80% Oper. Margin13.48% RSI (14)38.12 Volatility6.69% 8.40%
Employees- Debt/Eq0.72 Sales Y/Y TTM584.21% Profit Margin12.88% Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.66 EPS Q/Q58.78% Payout- Rel Volume0.03 Prev Close0.54
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% Earnings- Avg Volume219.42K Price0.54
SMA20-8.90% SMA50-13.00% SMA200-23.03% Trades Volume6,000 Change0.11%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Apr-22-24 04:01PM
Feb-06-24 07:05AM
Feb-05-24 04:01PM
Dec-08-23 08:40AM
Nov-28-23 04:01PM
09:48AM Loading…
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
04:01PM Loading…
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM
Jan-05-22 01:38PM
07:07PM Loading…
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
04:00PM
01:36PM
12:15PM
09:10AM
Dec-14-21 09:00PM
01:53PM
12:45PM
10:12AM
09:34AM
Dec-13-21 10:00PM
06:57PM
05:15PM
04:30PM
03:38PM
01:20PM
10:15AM
Dec-12-21 09:00PM
Dec-10-21 05:36PM
Dec-08-21 12:55PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DGP Co., Ltd.10% OwnerFeb 29 '24Sale1.323,400,0004,488,0000Mar 04 06:36 PM